Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 5
2013 4
2014 9
2015 12
2016 17
2017 8
2018 19
2019 26
2020 19
2021 11
2022 8
2023 0
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 32878782

127 results
Results by year
Filters applied: . Clear all
Page 1
ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F. Gridelli C, et al. Cancer Treat Rev. 2014 Mar;40(2):300-6. doi: 10.1016/j.ctrv.2013.07.002. Epub 2013 Aug 7. Cancer Treat Rev. 2014. PMID: 23931927 Review.
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, Gadgeel SM, Cheema P, Pavlakis N, de Marinis F, Cho BC, Zhang L, Moro-Sibilot D, Liu T, Bordogna W, Balas B, Müller B, Shaw AT. Camidge DR, et al. J Thorac Oncol. 2019 Jul;14(7):1233-1243. doi: 10.1016/j.jtho.2019.03.007. Epub 2019 Mar 20. J Thorac Oncol. 2019. PMID: 30902613 Free article. Clinical Trial.
Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines.
Chen Y, Ma G, Su C, Wu P, Wang H, Song X, Yu Q, Zeng A, Zhou S. Chen Y, et al. Anticancer Drugs. 2018 Nov;29(10):935-943. doi: 10.1097/CAD.0000000000000667. Anticancer Drugs. 2018. PMID: 30074936
Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405).
Isozaki H, Hotta K, Ichihara E, Takigawa N, Ohashi K, Kubo T, Ninomiya T, Ninomiya K, Oda N, Yoshioka H, Ichikawa H, Inoue M, Takata I, Shibayama T, Kuyama S, Sugimoto K, Harada D, Harita S, Sendo T, Tanimoto M, Kiura K. Isozaki H, et al. Clin Lung Cancer. 2016 Nov;17(6):602-605. doi: 10.1016/j.cllc.2016.05.005. Epub 2016 Jun 2. Clin Lung Cancer. 2016. PMID: 27405684 Clinical Trial.
127 results